How can Immunoscore® help the management of stage II patients?

- Identifies with Immunoscore® a greater prognosis value than traditional measurements
- Refines patients’ risk profile
- Helps to spare patients from unnecessary chemotherapy
- Adjusts treatment decision and improves colon cancer patients’ management

Robert, 76-year-old

- T3N0M0
- Partial Descending Colon
- Lack of differentiation
  He is clinically at a higher risk

Considered as a candidate for chemotherapy

“How Immunoscore® is the piece of the puzzle completing the information for your therapeutic decision”

Robert has an Immunoscore High

His immune system is responding to fight cancer

Patients with an Immunoscore High have a good prognosis and might be spared from chemotherapy.
CLINICAL UTILITY

Prognostic Value of Immunoscore® in stage II

Validated on the international SITC study among untreated Stage II patients (n=1130), Immunoscore® refines prognosis and identifies a sub-group of high clinical risk patients (Immunoscore High), who have similar clinical outcomes to low clinical risk patients (5-year recurrence risk: High-risk patients with IS High=13% vs Low-risk patients =11%).

Among high-risk patients, 7 out of 10 Patients have an Immunoscore High and may be spared from chemotherapy

TTR in Stage II untreated patients according to clinic-pathological risk, n=1130

Galon J, Hermitte F, Mlecnik B, et al., J Clin Oncol. 2019;37.4 (suppl; abstr 487)

IMMUNOSCORE® WORKFLOW

Pathology lab

Patient post resection surgery

Tumor block or unstained slides > Stain & Scan Slides > Compute Immunoscore® > Report Immunoscore® results

10 days

HalioDx lab

CONTACT & FOLLOW US

HalioDx - Luminy Biotech Entreprises
163 Avenue de Luminy - 13009 Marseille - FRANCE
Phone: +33 (0) 4 91 29 30 90 - Fax: +33 (0) 4 91 29 30 99

infos@haliodx.com

Copyright HalioDx® 11 2020, Design: ATCG Partners - Sophie Gieder - Photography Adobe Ref: ICO03-000-175 v01

immunoscore-colon.com